RESUMO
Despite recent advances in understanding the pathophysiologic mechanisms behind the thalassemia intermedia (TI) phenotype, data on the effects of treatment are deficient. To provide such data, we evaluated 584 TI patients for the associations between patient and disease characteristics, treatment received, and the rate of complications. The most common disease-related complications were osteoporosis, extramedullary hematopoeisis (EMH), hypogonadism, and cholelithiasis, followed by thrombosis, pulmonary hypertension (PHT), abnormal liver function, and leg ulcers. Hypothyroidism, heart failure, and diabetes mellitus were less frequently observed. On multivariate analysis, older age and splenectomy were independently associated with an increased risk of most disease-related complications. Transfusion therapy was protective for thrombosis, EMH, PHT, heart failure, cholelithiasis, and leg ulcers. However, transfusion therapy was associated with an increased risk of endocrinopathy. Iron chelation therapy was in turn protective for endocrinopathy and PHT. Hydroxyurea treatment was associated with an increased risk of hypogonadism yet was protective for EMH, PHT, leg ulcers, hypothyroidism, and osteoporosis. Attention should be paid to the impact of age on complications in TI, and the beneficial role of splenectomy deserves revisiting. This study provides evidence that calls for prospective evaluation of the roles of transfusion, iron chelation, and hydroxyurea therapy in TI patients.
Assuntos
Doenças Endêmicas/prevenção & controle , Prática Profissional , Talassemia/complicações , Talassemia/epidemiologia , Talassemia/terapia , Adolescente , Adulto , Idoso , Criança , Pré-Escolar , Doenças Endêmicas/estatística & dados numéricos , Doenças do Sistema Endócrino/epidemiologia , Doenças do Sistema Endócrino/prevenção & controle , Feminino , Hematopoese Extramedular , Humanos , Hipertensão Pulmonar/epidemiologia , Hipertensão Pulmonar/prevenção & controle , Hepatopatias/epidemiologia , Hepatopatias/prevenção & controle , Masculino , Pessoa de Meia-Idade , Prática Profissional/normas , Estudos Retrospectivos , Talassemia/prevenção & controle , Trombose/epidemiologia , Trombose/prevenção & controle , Adulto JovemRESUMO
The association between iron overload indices and pathology of the heart and liver in transfusion-dependent patients with ß thalassemia major (TM) has been extensively studied. Nonetheless, data on endocrine disease remains limited. This was a cross-sectional study of 382 TM patients treated with regular transfusions and desferrioxamine at the Thalassemia Center in Dubai, UAE. Retrieved data included demographics, splenectomy status, steady-state serum ferritin levels, and the presence of endocrinopathies (diabetes mellitus, hypothyroidism, hypoparathyroidism, and hypogonadism). Multivariate logistic regression analyses were used to determine which variables were independently associated with the occurrence of each endocrinopathy. The mean age of patients was 15.4 ± 7.6 years, with an equal sex distribution. The mean serum ferritin level was 2597.2 ± 1976.8 µg/l. The frequencies of specific endocrinopathies were diabetes mellitus (10.5%), hypothyroidism (6.3%), hypoparathyroidism (10.5%), and hypogonadism (25.9%). On multivariate logistic regression analysis, patients with a serum ferritin level >2,500 µg/l, but not >1,000-2,500 µg/l, were 3.53 times (95% CI 1.09-11.40) more likely to have diabetes mellitus, 3.25 times (95% CI 1.07-10.90) more likely to have hypothyroidism, 3.27 times (95% CI 1.27-8.39) more likely to have hypoparathyroidism, and 2.75 times (95% CI 1.38-5.49) more likely to have hypogonadism compared to patients with a serum ferritin level ≤1,000 µg/l. However, splenectomized patients with serum ferritin levels ≤2,500 µg/l had comparably high rates of all endocrinopathies as patients with serum ferritin levels >2,500 µg/l. Endocrinopathy is common in TM patients treated with desferrioxamine therapy, especially in patients with serum ferritin levels >2,500 µg/l or those splenectomized.
Assuntos
Doenças do Sistema Endócrino/sangue , Doenças do Sistema Endócrino/epidemiologia , Ferritinas/sangue , Talassemia beta/sangue , Talassemia beta/epidemiologia , Talassemia beta/terapia , Adolescente , Adulto , Transfusão de Sangue/métodos , Criança , Estudos Transversais , Desferroxamina/administração & dosagem , Desferroxamina/efeitos adversos , Doenças do Sistema Endócrino/complicações , Feminino , Humanos , Hipoparatireoidismo/epidemiologia , Hipoparatireoidismo/etiologia , Hipotireoidismo/epidemiologia , Hipotireoidismo/etiologia , Incidência , Quelantes de Ferro/administração & dosagem , Quelantes de Ferro/efeitos adversos , Sobrecarga de Ferro/epidemiologia , Sobrecarga de Ferro/etiologia , Masculino , Reação Transfusional , Adulto Jovem , Talassemia beta/complicaçõesRESUMO
BACKGROUND: Pulmonary hypertension (PHT) is a common yet poorly understood complication of ß thalassemia intermedia (TI). METHODS: We herein evaluated risk factors for PHT in TI, through comparing 64 TI patients with evidence of PHT by symptomatology and echocardiography (Group I) to age- and sex-matched TI patients without PHT (Group II). Retrieved data included demographics, laboratory parameters, clinical characteristics, and received treatments that may influence PHT development; and reflected the period prior to PHT occurrence in Group I. RESULTS: The mean age of Group I patients at development of PHT was 37.3±10.6years; with 44% being males. Among studied parameters, Group I patients were more likely to be splenectomized (4.9-times), transfusion-naive (3.5-times); hydroxyurea-naive (2.6-times), or iron chelation-naive (2.3-times); and have nucleated red blood cell count ≥300×10(6)/l (2.59-times) or a previous history of thromboembolic events (3.69-times). CONCLUSION: TI patients who eventually develop PHT may be identified early on by being splenectomized, having high nucleated red blood cell counts and a previous history of thromboembolism. Prospective clinical trials that evaluate the efficacy, safety, and cost effectiveness of transfusion, iron chelation, and hydroxyurea therapy in preventing PHT in TI are invited.